From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

Lymphoma Research Foundation: Treatment Options: CAR T-Cell Therapy

Leukemia and Lymphoma Society: CAR T-Cell Therapy

ASTCT 2022 National Fludarabine Shortage for HCT and CAR T-Cell Recipients: Frequently Asked Questions

American Cancer Society: CAR T-Cell Therapy and its Side Effects

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

NCCN: Immunotherapy Side Effects - CAR T-Cell Therapy

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

The EBMT/EHA CAR-T Cell Handbook

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

CAR T-Cell Therapy for Large B-Cell Lymphoma

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

CAR T-cell Therapy: Beyond the Storm

BMT infonet: CAR T-Cell therapy

ASTCT NucleusPlus: Insights on Emerging CAR-T Therapies

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Neurologic Toxicity Post-CAR T-Cell Therapy and CRS: Differentiating Symptoms and Individual Management

Fast Facts #12: BCMA Targets